Ibritumomab tiuxetan: all 51 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)TerminatedNCT01662102Phase 3Results posted
• Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like TherapyTerminatedNCT01510184Phase 3Results posted
• Zevalin and Velcade in Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT01497275Phase 2Results posted
• Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)CompletedNCT01490723Phase 2Results posted
• Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell TransplantationCompletedNCT00591630Phase 2Results posted
• Ibritumomab Tiuxetan (Zevalin)+ Rituximab MaintenanceTerminatedNCT00582166Phase 2Results posted
• Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent LymphomasCompletedNCT00493467Phase 2Results posted
• Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent LymphomasTerminatedNCT00493454Phase 2Results posted
• Zevalin-beam for Aggressive LymphomaCompletedNCT00491491Phase 3Results posted
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone LymphomaCompletedNCT00453102Phase 2Results posted
• Radioimmunotherapy With 90Y Zevalin for Orbital LymphomaCompletedNCT00387023Not applicableResults posted
• Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular LymphomaTerminatedNCT00372905Phase 1/2Results posted
• Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.TerminatedNCT00322218Phase 3Results posted
• Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular LymphomaCompletedNCT00290511Phase 2Results posted
• S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's LymphomaCompletedNCT00070018Phase 2Results posted
• Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00012298Phase 1/2Results posted
• Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular LymphomaCompletedNCT02063685Phase 3
• Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaStatus unknownNCT01811368Phase 2
• Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular LymphomaCompletedNCT01493479Phase 2
• Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular LymphomaCompletedNCT01446562Phase 2
• 90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell LymphomaCompletedNCT01157988Phase 2
• Zevalin Twice in Aggressive Non-Hodgkin LymphomaTerminatedNCT00902525Phase 2
• Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) TherapyCompletedNCT00859001Phase 2
• Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) TherapyCompletedNCT00850512Phase 2
• Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin LymphomaStatus unknownNCT00807196Phase 1/2
• Zevalin® First Line in Follicular LymphomaStatus unknownNCT00772655Phase 2
• High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell LymphomaCompletedNCT00761384Phase 1/2
• Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular LymphomaStatus unknownNCT00722930Phase 2
• ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)CompletedNCT00662948Phase 2
• Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse LymphomCompletedNCT00646750Phase 2
• Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)CompletedNCT00644371Phase 2
• Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)CompletedNCT00607854Phase 2
• A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin LymphomasCompletedNCT00521560Phase 2
• Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell LymphomaCompletedNCT00514475Phase 2
• Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)CompletedNCT00505232Phase 2
• Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's LymphomaStatus unknownNCT00463463Phase 3
• Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's LymphomaStatus unknownNCT00438581Phase 2
• Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHLWithdrawnNCT00414089Phase 2
• Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous TreatmentCompletedNCT00392691Phase 1
• Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell LymphomaTerminatedNCT00386321Phase 2
• Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.TerminatedNCT00354822Phase 2
• A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic RegimenWithdrawnNCT00319332Phase 3
• Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT00220285Phase 2
• Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's LymphomaCompletedNCT00193440Phase 2
• 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHLCompletedNCT00186589Phase 1
• Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's LymphomaCompletedNCT00168727Phase 4
• Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell LymphomaCompletedNCT00138086Phase 2
• Chemotherapy Followed by Zevalin for Relapsed Mantle Cell LymphomaCompletedNCT00119730Phase 2
• Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's LymphomaTerminatedNCT00057343Phase 3
• Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell LymphomaCompletedNCT00038623Phase 2
• Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00005592Phase 2

← Ibritumomab tiuxetan overview